扩展前列腺癌指数综合-26(EPIC-26)网络版:用于评估局限性前列腺癌治疗后健康相关生活质量的互联网工具验证
本研究开发EPIC-26网络版,并与电话版进行随机交叉验证。133名接受局部治疗的局限性前列腺癌患者随机分入网络优先组或电话优先组,完成两种方式问卷。结果显示五个领域组内相关系数均显著,无给药顺序效应,表明网络版与电话版高度一致。
要点
- EPIC-26网络版与电话版在五个领域均显示显著组内相关。
- 尿失禁r=0.96,尿刺激r=0.85,肠道功能r=0.61,性功能r=0.94,激素功能r=0.89。
- 问卷给药顺序无效应,验证了网络版在国际注册和临床实践中的可用性。
核心结论
- 网络版与电话版EPIC-26回答高度相关,所有领域均显示重测信度,无顺序效应。
- 验证了网络版EPIC-26可用于国际注册及临床实践与质量改进。
研究设计与样本
- 研究招募自PROST-QA和PROSTQA-RP2两个前瞻性纵向队列的局限性前列腺癌局部治疗患者。
- 181名受试者受邀,133名同意参与;随机分为网络优先组65例和电话优先组68例。
- 两组分别有37例和26例完成两种版本问卷,应答率44.4%。
主要发现
- 重测分析显示五个领域组内相关系数显著:尿失禁r=0.96,尿刺激r=0.85,肠道功能r=0.61,性功能r=0.94,激素功能r=0.89。
- 问卷给药顺序无效应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To test the validity of an Internet-based version of Expanded Prostate Cancer Index Composite (EPIC-26) versus the phone-based version. Most men will survive for years after treatment for localized prostate cancer (PCa) and may experience lasting treatment-related toxicities affecting health-related quality of life. The EPIC-26 is a validated instrument that measures health-related quality of life across 5 PCa-specific domains. Previously, EPIC-26 was administered via phone in a large multicenter clinical trial. METHODS: We developed an Internet-based version of EPIC-26. We recruited subjects from two prospective longitudinal study cohorts of PCa patients undergoing local therapy: PROST-QA, and PROSTQA-RP2. Subjects were randomized to either an "Internet-first" or "phone-first" group. Subjects were offered the alternate questionnaire modality 2 weeks after completing the initial modality. RESULTS: 181 subjects were offered enrollment; 133 agreed to participate. 65 subjects were randomized to the "Internet- first" group and 68 subjects to the "phone-first" group. Of these, 37 and 26 subjects respectively completed both questionnaire versions (response rate: 44.4%). Test-retest analysis showed significant intraclass correlations in all 5 domains of EPIC-26: urinary incontinence (r = 0.96), urinary irritation (r = 0.85), bowel function (r = 0.61), sexual function (r = 0.94), and hormonal function (r = 0.89). There was no effect of order of questionnaire administration. CONCLUSION: This study demonstrates excellent correlation of responses between Internet-based and phone-based EPIC-26 administration. All domains demonstrated test-retest reliability between modalities, without ordering effect. This validates the use of internet-based EPIC-26 in international registries as part of the International Consortium for Health Outcomes Measurement effort, and may facilitate its use in clinical practice and quality improvement.
引用
- Einstein DJ, Patil D, Chipman J, et al. Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate Cancer. Urology. 2019. PMID: 30790648. doi:10.1016/j.urology.2019.02.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。